Manifold Bio

manifold.bio →

-40%

est. 2Y upside i

HealthcareSeries A

Tissue-targeted medicines, designed in vivo.

Rank

#3596

Sector

Biotechnology

Est. Liquidity

~5Y

Data Quality

Data: Low

Equity analysis is severely constrained by missing valuation and revenue data.

Last updated: July 3, 2026

Bull (10%)0%

Entry valuation unknown; cannot compute upside. Bull scenario assumes successful exit via IPO or acquisition at significant premium, but no numeric estimate possible.

Base (50%)0%

Entry valuation unknown; cannot compute upside. Base scenario reflects moderate progress but no exit within 2 years.

Bear (40%)-100%

Entry valuation unknown; bear scenario assumes liquidation or down round, with common stock worthless after preference.

Est. time to liquidity~5.0 years

Preference Stack Risk

high

Funding Intensity

0%

Total funding of $77M could represent a significant preference over common stock if valuation is below that amount.

Dilution Risk

high

Capital-intensive biotech likely requires further rounds, diluting common shareholders.

Secondary Liquidity

none

No secondary market transactions reported; liquidity expected only upon exit.

View all 6 open roles at Manifold Bio →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Manifold Bio's data — designed to show you've done your homework.

  • 1

    “How does Manifold's barcoding technology compare to Denali's blood-brain barrier shuttle?”

  • 2

    “What is the timeline to IND and how does the pipeline de-risk?”

  • 3

    “Given the capital intensity, what is the expected dilution over the next 2 years?”

Community

Valuation Sentiment

Our model estimates -40% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.